Pharma and Biotech Leaders Weigh Benefits and Risks of Genomic Technologies | GenomeWeb

PRINCETON, NJ, Dec. 4 - While the pharmaceutical industry may agree that genomic technology will impact the drug discovery process, the jury is still out on what that impact may be, according to panelists at the Economist 's Pharmaceuticals 2001 conference, held December 3-4 in Princeton, NJ.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.